Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 246

1.

Integrative Analysis of Novel Metabolic Subtypes in Pancreatic Cancer Fosters New Prognostic Biomarkers.

Follia L, Ferrero G, Mandili G, Beccuti M, Giordano D, Spadi R, Satolli MA, Evangelista A, Katayama H, Hong W, Momin AA, Capello M, Hanash SM, Novelli F, Cordero F.

Front Oncol. 2019 Feb 27;9:115. doi: 10.3389/fonc.2019.00115. eCollection 2019.

2.

Whole genome-derived tiled peptide arrays detect pre-diagnostic autoantibody signatures in non-small cell lung cancer.

Yan Y, Sun N, Wang H, Kobayashi M, Ladd JJ, Long JP, Lo KC, Patel J, Sullivan E, Albert T, Goodman GE, Do KA, Hanash SM.

Cancer Res. 2019 Feb 5. pii: canres.1536.2018. doi: 10.1158/0008-5472.CAN-18-1536. [Epub ahead of print]

PMID:
30723114
3.

Exosomes harbor B cell targets in pancreatic adenocarcinoma and exert decoy function against complement-mediated cytotoxicity.

Capello M, Vykoukal JV, Katayama H, Bantis LE, Wang H, Kundnani DL, Aguilar-Bonavides C, Aguilar M, Tripathi SC, Dhillon DS, Momin AA, Peters H, Katz MH, Alvarez H, Bernard V, Ferri-Borgogno S, Brand R, Adler DG, Firpo MA, Mulvihill SJ, Molldrem JJ, Feng Z, Taguchi A, Maitra A, Hanash SM.

Nat Commun. 2019 Jan 16;10(1):254. doi: 10.1038/s41467-018-08109-6.

4.

Testing the gene expression classification of the EMT spectrum.

Jia D, George JT, Tripathi SC, Kundnani DL, Lu M, Hanash SM, Onuchic JN, Jolly MK, Levine H.

Phys Biol. 2019 Jan 18;16(2):025002. doi: 10.1088/1478-3975/aaf8d4.

PMID:
30557866
5.

Hybrid epithelial/mesenchymal phenotypes promote metastasis and therapy resistance across carcinomas.

Jolly MK, Somarelli JA, Sheth M, Biddle A, Tripathi SC, Armstrong AJ, Hanash SM, Bapat SA, Rangarajan A, Levine H.

Pharmacol Ther. 2019 Feb;194:161-184. doi: 10.1016/j.pharmthera.2018.09.007. Epub 2018 Sep 28. Review.

PMID:
30268772
6.

Blood based biomarkers beyond genomics for lung cancer screening.

Hanash SM, Ostrin EJ, Fahrmann JF.

Transl Lung Cancer Res. 2018 Jun;7(3):327-335. doi: 10.21037/tlcr.2018.05.13. Review.

7.

Assessment of Lung Cancer Risk on the Basis of a Biomarker Panel of Circulating Proteins.

Integrative Analysis of Lung Cancer Etiology and Risk (INTEGRAL) Consortium for Early Detection of Lung Cancer, Guida F, Sun N, Bantis LE, Muller DC, Li P, Taguchi A, Dhillon D, Kundnani DL, Patel NJ, Yan Q, Byrnes G, Moons KGM, Tjønneland A, Panico S, Agnoli C, Vineis P, Palli D, Bueno-de-Mesquita B, Peeters PH, Agudo A, Huerta JM, Dorronsoro M, Barranco MR, Ardanaz E, Travis RC, Byrne KS, Boeing H, Steffen A, Kaaks R, Hüsing A, Trichopoulou A, Lagiou P, La Vecchia C, Severi G, Boutron-Ruault MC, Sandanger TM, Weiderpass E, Nøst TH, Tsilidis K, Riboli E, Grankvist K, Johansson M, Goodman GE, Feng Z, Brennan P, Johansson M, Hanash SM.

JAMA Oncol. 2018 Oct 1;4(10):e182078. doi: 10.1001/jamaoncol.2018.2078. Epub 2018 Oct 11.

PMID:
30003238
8.

β-Catenin maintains lung epithelial progenitors after lung specification.

Ostrin EJ, Little DR, Gerner-Mauro KN, Sumner EA, Ríos-Corzo R, Ambrosio E, Holt SE, Forcioli-Conti N, Akiyama H, Hanash SM, Kimura S, Huang SXL, Chen J.

Development. 2018 Mar 9;145(5). pii: dev160788. doi: 10.1242/dev.160788.

9.

Detection and localization of surgically resectable cancers with a multi-analyte blood test.

Cohen JD, Li L, Wang Y, Thoburn C, Afsari B, Danilova L, Douville C, Javed AA, Wong F, Mattox A, Hruban RH, Wolfgang CL, Goggins MG, Dal Molin M, Wang TL, Roden R, Klein AP, Ptak J, Dobbyn L, Schaefer J, Silliman N, Popoli M, Vogelstein JT, Browne JD, Schoen RE, Brand RE, Tie J, Gibbs P, Wong HL, Mansfield AS, Jen J, Hanash SM, Falconi M, Allen PJ, Zhou S, Bettegowda C, Diaz LA Jr, Tomasetti C, Kinzler KW, Vogelstein B, Lennon AM, Papadopoulos N.

Science. 2018 Feb 23;359(6378):926-930. doi: 10.1126/science.aar3247. Epub 2018 Jan 18.

10.

HIV Infection and Circulating Levels of Prosurfactant Protein B and Surfactant Protein D.

Shiels MS, Kirk GD, Drummond MB, Dhillon D, Hanash SM, Taguchi A, Engels EA.

J Infect Dis. 2018 Jan 17;217(3):413-417. doi: 10.1093/infdis/jix510.

11.

Plasma-derived extracellular vesicle proteins as a source of biomarkers for lung adenocarcinoma.

Vykoukal J, Sun N, Aguilar-Bonavides C, Katayama H, Tanaka I, Fahrmann JF, Capello M, Fujimoto J, Aguilar M, Wistuba II, Taguchi A, Ostrin EJ, Hanash SM.

Oncotarget. 2017 Sep 8;8(56):95466-95480. doi: 10.18632/oncotarget.20748. eCollection 2017 Nov 10.

12.

Numb prevents a complete epithelial-mesenchymal transition by modulating Notch signalling.

Bocci F, Jolly MK, Tripathi SC, Aguilar M, Hanash SM, Levine H, Onuchic JN.

J R Soc Interface. 2017 Nov;14(136). pii: 20170512. doi: 10.1098/rsif.2017.0512.

13.

Reduced IL-6 levels and tumor-associated phospho-STAT3 are associated with reduced tumor development in a mouse model of lung cancer chemoprevention with myo-inositol.

Unver N, Delgado O, Zeleke K, Cumpian A, Tang X, Caetano MS, Wang H, Katayama H, Yu H, Szabo E, Wistuba II, Moghaddam SJ, Hanash SM, Ostrin EJ.

Int J Cancer. 2018 Apr 1;142(7):1405-1417. doi: 10.1002/ijc.31152. Epub 2017 Dec 23.

PMID:
29134640
14.

HSP90 inhibition enhances cancer immunotherapy by upregulating interferon response genes.

Mbofung RM, McKenzie JA, Malu S, Zhang M, Peng W, Liu C, Kuiatse I, Tieu T, Williams L, Devi S, Ashkin E, Xu C, Huang L, Zhang M, Talukder AH, Tripathi SC, Khong H, Satani N, Muller FL, Roszik J, Heffernan T, Allison JP, Lizee G, Hanash SM, Proia D, Amaria R, Davis RE, Hwu P.

Nat Commun. 2017 Sep 6;8(1):451. doi: 10.1038/s41467-017-00449-z.

15.

Combined circulating tumor DNA and protein biomarker-based liquid biopsy for the earlier detection of pancreatic cancers.

Cohen JD, Javed AA, Thoburn C, Wong F, Tie J, Gibbs P, Schmidt CM, Yip-Schneider MT, Allen PJ, Schattner M, Brand RE, Singhi AD, Petersen GM, Hong SM, Kim SC, Falconi M, Doglioni C, Weiss MJ, Ahuja N, He J, Makary MA, Maitra A, Hanash SM, Dal Molin M, Wang Y, Li L, Ptak J, Dobbyn L, Schaefer J, Silliman N, Popoli M, Goggins MG, Hruban RH, Wolfgang CL, Klein AP, Tomasetti C, Papadopoulos N, Kinzler KW, Vogelstein B, Lennon AM.

Proc Natl Acad Sci U S A. 2017 Sep 19;114(38):10202-10207. doi: 10.1073/pnas.1704961114. Epub 2017 Sep 5.

16.

In vivo loss-of-function screens identify KPNB1 as a new druggable oncogene in epithelial ovarian cancer.

Kodama M, Kodama T, Newberg JY, Katayama H, Kobayashi M, Hanash SM, Yoshihara K, Wei Z, Tien JC, Rangel R, Hashimoto K, Mabuchi S, Sawada K, Kimura T, Copeland NG, Jenkins NA.

Proc Natl Acad Sci U S A. 2017 Aug 29;114(35):E7301-E7310. doi: 10.1073/pnas.1705441114. Epub 2017 Aug 15.

17.

Thy-1+ Cancer-associated Fibroblasts Adversely Impact Lung Cancer Prognosis.

Schliekelman MJ, Creighton CJ, Baird BN, Chen Y, Banerjee P, Bota-Rabassedas N, Ahn YH, Roybal JD, Chen F, Zhang Y, Mishra DK, Kim MP, Liu X, Mino B, Villalobos P, Rodriguez-Canales J, Behrens C, Wistuba II, Hanash SM, Kurie JM.

Sci Rep. 2017 Jul 25;7(1):6478. doi: 10.1038/s41598-017-06922-5.

18.

MCAM Mediates Chemoresistance in Small-Cell Lung Cancer via the PI3K/AKT/SOX2 Signaling Pathway.

Tripathi SC, Fahrmann JF, Celiktas M, Aguilar M, Marini KD, Jolly MK, Katayama H, Wang H, Murage EN, Dennison JB, Watkins DN, Levine H, Ostrin EJ, Taguchi A, Hanash SM.

Cancer Res. 2017 Aug 15;77(16):4414-4425. doi: 10.1158/0008-5472.CAN-16-2874. Epub 2017 Jun 23.

19.

Epithelial/mesenchymal plasticity: how have quantitative mathematical models helped improve our understanding?

Jolly MK, Tripathi SC, Somarelli JA, Hanash SM, Levine H.

Mol Oncol. 2017 Jul;11(7):739-754. doi: 10.1002/1878-0261.12084. Epub 2017 Jun 19. Review.

20.

Neuropilin-1 mediates neutrophil elastase uptake and cross-presentation in breast cancer cells.

Kerros C, Tripathi SC, Zha D, Mehrens JM, Sergeeva A, Philips AV, Qiao N, Peters HL, Katayama H, Sukhumalchandra P, Ruisaard KE, Perakis AA, St John LS, Lu S, Mittendorf EA, Clise-Dwyer K, Herrmann AC, Alatrash G, Toniatti C, Hanash SM, Ma Q, Molldrem JJ.

J Biol Chem. 2017 Jun 16;292(24):10295-10305. doi: 10.1074/jbc.M116.773051. Epub 2017 May 3.

21.

Role of CPS1 in Cell Growth, Metabolism and Prognosis in LKB1-Inactivated Lung Adenocarcinoma.

Çeliktas M, Tanaka I, Tripathi SC, Fahrmann JF, Aguilar-Bonavides C, Villalobos P, Delgado O, Dhillon D, Dennison JB, Ostrin EJ, Wang H, Behrens C, Do KA, Gazdar AF, Hanash SM, Taguchi A.

J Natl Cancer Inst. 2017 Mar 1;109(3):1-9. doi: 10.1093/jnci/djw231.

22.

Sequential Validation of Blood-Based Protein Biomarker Candidates for Early-Stage Pancreatic Cancer.

Capello M, Bantis LE, Scelo G, Zhao Y, Li P, Dhillon DS, Patel NJ, Kundnani DL, Wang H, Abbruzzese JL, Maitra A, Tempero MA, Brand R, Firpo MA, Mulvihill SJ, Katz MH, Brennan P, Feng Z, Taguchi A, Hanash SM.

J Natl Cancer Inst. 2017 Apr 1;109(4). doi: 10.1093/jnci/djw266.

23.

Deubiquitinase USP18 Loss Mislocalizes and Destabilizes KRAS in Lung Cancer.

Mustachio LM, Lu Y, Tafe LJ, Memoli V, Rodriguez-Canales J, Mino B, Villalobos PA, Wistuba I, Katayama H, Hanash SM, Roszik J, Kawakami M, Cho KJ, Hancock JF, Chinyengetere F, Hu S, Liu X, Freemantle SJ, Dmitrovsky E.

Mol Cancer Res. 2017 Jul;15(7):905-914. doi: 10.1158/1541-7786.MCR-16-0369. Epub 2017 Feb 27.

24.

Distinguishing mechanisms underlying EMT tristability.

Jia D, Jolly MK, Tripathi SC, Den Hollander P, Huang B, Lu M, Celiktas M, Ramirez-Peña E, Ben-Jacob E, Onuchic JN, Hanash SM, Mani SA, Levine H.

Cancer Converg. 2017;1(1):2. doi: 10.1186/s41236-017-0005-8. Epub 2017 Nov 1.

25.

Protein and glycomic plasma markers for early detection of adenoma and colon cancer.

Rho JH, Ladd JJ, Li CI, Potter JD, Zhang Y, Shelley D, Shibata D, Coppola D, Yamada H, Toyoda H, Tada T, Kumada T, Brenner DE, Hanash SM, Lampe PD.

Gut. 2018 Mar;67(3):473-484. doi: 10.1136/gutjnl-2016-312794. Epub 2016 Nov 7.

26.

Lysyl Hydroxylase 2 Is Secreted by Tumor Cells and Can Modify Collagen in the Extracellular Space.

Chen Y, Guo H, Terajima M, Banerjee P, Liu X, Yu J, Momin AA, Katayama H, Hanash SM, Burns AR, Fields GB, Yamauchi M, Kurie JM.

J Biol Chem. 2016 Dec 9;291(50):25799-25808. Epub 2016 Nov 1.

27.

The Emerging Role of B Cells in Tumor Immunity.

Tsou P, Katayama H, Ostrin EJ, Hanash SM.

Cancer Res. 2016 Oct 1;76(19):5597-5601. Epub 2016 Sep 15. Review.

28.

A statistical method for detecting differentially expressed SNVs based on next-generation RNA-seq data.

Fu R, Wang P, Ma W, Taguchi A, Wong CH, Zhang Q, Gazdar A, Hanash SM, Zhou Q, Zhong H, Feng Z.

Biometrics. 2017 Mar;73(1):42-51. doi: 10.1111/biom.12548. Epub 2016 Jun 8.

29.

Stability of the hybrid epithelial/mesenchymal phenotype.

Jolly MK, Tripathi SC, Jia D, Mooney SM, Celiktas M, Hanash SM, Mani SA, Pienta KJ, Ben-Jacob E, Levine H.

Oncotarget. 2016 May 10;7(19):27067-84. doi: 10.18632/oncotarget.8166.

30.

Immunoproteasome deficiency is a feature of non-small cell lung cancer with a mesenchymal phenotype and is associated with a poor outcome.

Tripathi SC, Peters HL, Taguchi A, Katayama H, Wang H, Momin A, Jolly MK, Celiktas M, Rodriguez-Canales J, Liu H, Behrens C, Wistuba II, Ben-Jacob E, Levine H, Molldrem JJ, Hanash SM, Ostrin EJ.

Proc Natl Acad Sci U S A. 2016 Mar 15;113(11):E1555-64. doi: 10.1073/pnas.1521812113. Epub 2016 Feb 29.

31.

EGFR Signaling Enhances Aerobic Glycolysis in Triple-Negative Breast Cancer Cells to Promote Tumor Growth and Immune Escape.

Lim SO, Li CW, Xia W, Lee HH, Chang SS, Shen J, Hsu JL, Raftery D, Djukovic D, Gu H, Chang WC, Wang HL, Chen ML, Huo L, Chen CH, Wu Y, Sahin A, Hanash SM, Hortobagyi GN, Hung MC.

Cancer Res. 2016 Mar 1;76(5):1284-96. doi: 10.1158/0008-5472.CAN-15-2478. Epub 2016 Jan 12.

32.

Cancer-Associated Fibroblasts Induce a Collagen Cross-link Switch in Tumor Stroma.

Pankova D, Chen Y, Terajima M, Schliekelman MJ, Baird BN, Fahrenholtz M, Sun L, Gill BJ, Vadakkan TJ, Kim MP, Ahn YH, Roybal JD, Liu X, Parra Cuentas ER, Rodriguez J, Wistuba II, Creighton CJ, Gibbons DL, Hicks JM, Dickinson ME, West JL, Grande-Allen KJ, Hanash SM, Yamauchi M, Kurie JM.

Mol Cancer Res. 2016 Mar;14(3):287-95. doi: 10.1158/1541-7786.MCR-15-0307. Epub 2015 Dec 2.

33.

MAPRE1 as a plasma biomarker for early-stage colorectal cancer and adenomas.

Taguchi A, Rho JH, Yan Q, Zhang Y, Zhao Y, Xu H, Tripathi SC, Wang H, Brenner DE, Kucherlapati M, Kucherlapati R, Boutin AT, Wang YA, DePinho RA, Feng Z, Lampe PD, Hanash SM.

Cancer Prev Res (Phila). 2015 Nov;8(11):1112-9. doi: 10.1158/1940-6207.CAPR-15-0077. Epub 2015 Sep 4.

34.

Carboxylesterase 2 as a Determinant of Response to Irinotecan and Neoadjuvant FOLFIRINOX Therapy in Pancreatic Ductal Adenocarcinoma.

Capello M, Lee M, Wang H, Babel I, Katz MH, Fleming JB, Maitra A, Wang H, Tian W, Taguchi A, Hanash SM.

J Natl Cancer Inst. 2015 May 29;107(8). pii: djv132. doi: 10.1093/jnci/djv132. Print 2015 Aug.

35.

Systemic Metabolomic Changes in Blood Samples of Lung Cancer Patients Identified by Gas Chromatography Time-of-Flight Mass Spectrometry.

Miyamoto S, Taylor SL, Barupal DK, Taguchi A, Wohlgemuth G, Wikoff WR, Yoneda KY, Gandara DR, Hanash SM, Kim K, Fiehn O.

Metabolites. 2015 Apr 9;5(2):192-210. doi: 10.3390/metabo5020192.

36.

Molecular portraits of epithelial, mesenchymal, and hybrid States in lung adenocarcinoma and their relevance to survival.

Schliekelman MJ, Taguchi A, Zhu J, Dai X, Rodriguez J, Celiktas M, Zhang Q, Chin A, Wong CH, Wang H, McFerrin L, Selamat SA, Yang C, Kroh EM, Garg KS, Behrens C, Gazdar AF, Laird-Offringa IA, Tewari M, Wistuba II, Thiery JP, Hanash SM.

Cancer Res. 2015 May 1;75(9):1789-800. doi: 10.1158/0008-5472.CAN-14-2535. Epub 2015 Mar 5.

37.

Proteomic signatures associated with p53 mutational status in lung adenocarcinoma.

Taguchi A, Delgado O, Celiktaş M, Katayama H, Wang H, Gazdar AF, Hanash SM.

Proteomics. 2014 Dec;14(23-24):2750-9. doi: 10.1002/pmic.201400378. Epub 2014 Nov 20.

38.

Modeling putative therapeutic implications of exosome exchange between tumor and immune cells.

Lu M, Huang B, Hanash SM, Onuchic JN, Ben-Jacob E.

Proc Natl Acad Sci U S A. 2014 Oct 7;111(40):E4165-74. doi: 10.1073/pnas.1416745111. Epub 2014 Sep 22.

39.

A search for novel cancer/testis antigens in lung cancer identifies VCX/Y genes, expanding the repertoire of potential immunotherapeutic targets.

Taguchi A, Taylor AD, Rodriguez J, Celiktaş M, Liu H, Ma X, Zhang Q, Wong CH, Chin A, Girard L, Behrens C, Lam WL, Lam S, Minna JD, Wistuba II, Gazdar AF, Hanash SM.

Cancer Res. 2014 Sep 1;74(17):4694-705. doi: 10.1158/0008-5472.CAN-13-3725. Epub 2014 Jun 26.

40.

Mining the pre-diagnostic antibody repertoire of TgMMTV-neu mice to identify autoantibodies useful for the early detection of human breast cancer.

Mao J, Ladd J, Gad E, Rastetter L, Johnson MM, Marzbani E, Childs JS, Lu H, Dang Y, Broussard E, Stanton SE, Hanash SM, Disis ML.

J Transl Med. 2014 May 10;12:121. doi: 10.1186/1479-5876-12-121.

41.

Proteomic risk markers for coronary heart disease and stroke: validation and mediation of randomized trial hormone therapy effects on these diseases.

Prentice RL, Zhao S, Johnson M, Aragaki A, Hsia J, Jackson RD, Rossouw JE, Manson JE, Hanash SM.

Genome Med. 2013 Dec 27;5(12):112. doi: 10.1186/gm517. eCollection 2013.

42.

Mouse to human blood-based cancer biomarker discovery strategies.

Hanash SM, Taguchi A.

Cold Spring Harb Protoc. 2014 Feb 1;2014(2):144-9. doi: 10.1101/pdb.top078808. Review.

PMID:
24173314
43.

A novel soluble form of Tim-3 associated with severe graft-versus-host disease.

Hansen JA, Hanash SM, Tabellini L, Baik C, Lawler RL, Grogan BM, Storer B, Chin A, Johnson M, Wong CH, Zhang Q, Martin PJ, McDonald GB.

Biol Blood Marrow Transplant. 2013 Sep;19(9):1323-30. doi: 10.1016/j.bbmt.2013.06.011. Epub 2013 Jun 17.

44.

Fibulin-2 is a driver of malignant progression in lung adenocarcinoma.

Baird BN, Schliekelman MJ, Ahn YH, Chen Y, Roybal JD, Gill BJ, Mishra DK, Erez B, O'Reilly M, Yang Y, Patel M, Liu X, Thilaganathan N, Larina IV, Dickinson ME, West JL, Gibbons DL, Liu DD, Kim MP, Hicks JM, Wistuba II, Hanash SM, Kurie JM.

PLoS One. 2013 Jun 10;8(6):e67054. doi: 10.1371/journal.pone.0067054. Print 2013.

45.

Enrichment strategies in glycomics-based lung cancer biomarker development.

Ruhaak LR, Nguyen UT, Stroble C, Taylor SL, Taguchi A, Hanash SM, Lebrilla CB, Kim K, Miyamoto S.

Proteomics Clin Appl. 2013 Oct;7(9-10):664-76. doi: 10.1002/prca.201200131. Epub 2013 Aug 6.

46.

Identification of potential glycan cancer markers with sialic acid attached to sialic acid and up-regulated fucosylated galactose structures in epidermal growth factor receptor secreted from A431 cell line.

Wu SL, Taylor AD, Lu Q, Hanash SM, Im H, Snyder M, Hancock WS.

Mol Cell Proteomics. 2013 May;12(5):1239-49. doi: 10.1074/mcp.M112.024554. Epub 2013 Jan 31.

47.

Imaging a functional tumorigenic biomarker in the transformed epithelium.

LeBeau AM, Lee M, Murphy ST, Hann BC, Warren RS, Delos Santos R, Kurhanewicz J, Hanash SM, VanBrocklin HF, Craik CS.

Proc Natl Acad Sci U S A. 2013 Jan 2;110(1):93-8. doi: 10.1073/pnas.1218694110. Epub 2012 Dec 17.

48.

Unleashing the power of proteomics to develop blood-based cancer markers.

Taguchi A, Hanash SM.

Clin Chem. 2013 Jan;59(1):119-26. doi: 10.1373/clinchem.2012.184572. Epub 2012 Oct 24. Review.

49.

Linker for activation of T-cell family member2 (LAT2) a lipid raft adaptor protein for AKT signaling, is an early mediator of alkylphospholipid anti-leukemic activity.

Thomé CH, dos Santos GA, Ferreira GA, Scheucher PS, Izumi C, Leopoldino AM, Simão AM, Ciancaglini P, de Oliveira KT, Chin A, Hanash SM, Falcão RP, Rego EM, Greene LJ, Faça VM.

Mol Cell Proteomics. 2012 Dec;11(12):1898-912. doi: 10.1074/mcp.M112.019661. Epub 2012 Sep 22.

50.

Discovery and preliminary confirmation of novel early detection biomarkers for triple-negative breast cancer using preclinical plasma samples from the Women's Health Initiative observational study.

Li CI, Mirus JE, Zhang Y, Ramirez AB, Ladd JJ, Prentice RL, McIntosh MW, Hanash SM, Lampe PD.

Breast Cancer Res Treat. 2012 Sep;135(2):611-8. doi: 10.1007/s10549-012-2204-4. Epub 2012 Aug 19.

Supplemental Content

Loading ...
Support Center